Tigatuzumab

立即咨询

Tigatuzumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

918127-53-4

CS-1008
Anti-Human TRAIL-R2 Recombinant Antibody

Tigatuzumab (CS-1008) 是一种靶向 death receptor 5 (DR5) 的人源 IgG1 单克隆抗体。Tigatuzumab 可诱导癌细胞凋亡，并抑制体内抑制肿瘤生长。Tigatuzumab 可用于癌症研究。

生物活性

Tigatuzumab (CS-1008) is a humanizedIgG1monoclonal antibody targetsdeath receptor 5(DR5). Tigatuzumab induces cellapoptosisofcancercells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research ofcancer^[1].

体外研究
(In Vitro)

Tigatuzumab is sensitive to MIA PaCa-2 cells and BxPC-3 cells with IC₅₀values of 2.95 and 8.21 μg/mL, respectively^[1].
Tigatuzumab (3-8 μg/mL; 5 h) induces apoptosis of cancer cells^[1].

Apoptosis Analysis^[1]

Cell Line:	MIA PaCa-2 and BxPC-3 cell lines
Concentration:	3 and 8 μg/mL
Incubation Time:	5 hours
Result:	Induced cell apoptosis, and the methionine restriction increased the caspase activation and apoptosis in pancreatic cancer cells.

体内研究
(In Vivo)

Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model^[1].

Animal Model:	Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection^[1]
Dosage:	3 mg/kg
Administration:	Intravenous injection; 3 mg/kg weekly for 4 weeks
Result:	Reduced the tumor volume and decreased the density of viable cancer cells in tumors.

分子量

144.6 (kDa)

CAS 号

918127-53-4

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.